PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Aclaris Therapeutics, Inc. (ACRS)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS00461U1051
CUSIP00461U105
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$81.56M
EPS-$1.27
PEG Ratio-0.13
Revenue (TTM)$31.25M
Gross Profit (TTM)-$60.02M
EBITDA (TTM)-$117.57M
Year Range$0.59 - $11.12
Target Price$1.80
Short %9.91%
Short Ratio4.32

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ACRS

Aclaris Therapeutics, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Aclaris Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%100.00%150.00%OctoberNovemberDecember2024FebruaryMarch
-88.60%
162.97%
ACRS (Aclaris Therapeutics, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Aclaris Therapeutics, Inc. had a return of 20.00% year-to-date (YTD) and -84.33% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date20.00%10.04%
1 month4.13%3.53%
6 months-81.08%22.79%
1 year-84.33%32.16%
5 years (annualized)-26.84%13.15%
10 years (annualized)N/A10.96%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
202410.48%2.59%
2023-24.21%-8.42%-27.30%-82.44%20.04%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

This table presents risk-adjusted performance metrics for Aclaris Therapeutics, Inc. (ACRS) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
ACRS
Aclaris Therapeutics, Inc.
-0.74
^GSPC
S&P 500
2.76

Sharpe Ratio

The current Aclaris Therapeutics, Inc. Sharpe ratio is -0.74. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00OctoberNovemberDecember2024FebruaryMarch
-0.74
2.76
ACRS (Aclaris Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Aclaris Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%OctoberNovemberDecember2024FebruaryMarch
-96.18%
0
ACRS (Aclaris Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Aclaris Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Aclaris Therapeutics, Inc. was 98.05%, occurring on Nov 13, 2023. The portfolio has not yet recovered.

The current Aclaris Therapeutics, Inc. drawdown is 96.18%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-98.05%Apr 18, 20171656Nov 13, 2023
-49.56%Dec 23, 201563Mar 24, 2016173Nov 29, 2016236
-19.68%Dec 19, 201634Feb 7, 201713Feb 27, 201747
-13.11%Nov 24, 20157Dec 3, 20159Dec 16, 201516
-12.04%Mar 7, 201711Mar 21, 201718Apr 17, 201729

Volatility

Volatility Chart

The current Aclaris Therapeutics, Inc. volatility is 23.07%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%50.00%100.00%150.00%200.00%OctoberNovemberDecember2024FebruaryMarch
23.07%
2.82%
ACRS (Aclaris Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Aclaris Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items